Evaluation of the TEG® platelet mapping™ assay in blood donors

被引：94

作者：

Bochsen L. ^{[1
]}

Wiinberg B. ^{[2
]}

Kjelgaard-Hansen M. ^{[2
]}

Steinbrüchel D.A. ^{[3
]}

Johansson P.I. ^{[1
]}

机构：

[1] Department of Clinical Immunology, Rigshospitalet, University of Copenhagen

[2] Department of Small Animal Clinical Sciences, The Small Animal Hospital, University of Copenhagen

[3] Department of Cardiothoracic Surgery, Rigshospitalet, University of Copenhagen

来源：

Thrombosis Journal | / 5卷 / 1期

关键词：

Arachidonic Acid; Clopidogrel; Maximal Amplitude; Antiplatelet Therapy; Platelet Mapping;

D O I：

10.1186/1477-9560-5-3

中图分类号：

学科分类号：

摘要：

Background: Monitoring of antiplatelet therapy in patients at cardiovascular risk is difficult because existing platelet function tests are too sophisticated for clinical routine. The whole blood TEG® Platelet Mapping™ assay measures clot strength as maximal amplitude (MA) and enables for quantification of platelet function, including the contribution of the adenosine diphosphate (ADP) and thromboxane A2 (TxA2) receptors to clot formation. Methods: In 43 healthy blood donors, the analytical (CVa) and inter-individual variability (CVg) of the TEG® Platelet Mapping™ assay were determined together with platelet receptor inhibition in response to arachidonic acid (AA) and ADP. Results: The CVa of the assay for maximal platelet contribution to clot strength (MAThrombin) was 3.5%, for the fibrin contribution to clot strength (MAFibrin) 5.2%, for MAAA 4.5% and for MAADP it was 6.6%. The MAThrombin CVg was 2.8%, MAFibrin 4.7%, MAAA 6.6% and for MAADP it was 26.2%. Females had a higher MAThrombin compared to males (62.8 vs. 58.4 mm, p = 0.005). The platelet TxA2 receptor inhibition was 1.2% (range 0-10%) and lower than for the ADP receptor (18.6% (0-58%); p < 0.0001). Conclusion: The high variability in ADP receptor inhibition may explain both the differences in response to ADP receptor inhibitor therapy and why major bleeding sometimes develops during surgery in patients not treated with ADP receptor inhibitors. An analytical variation of ∼ 5% for the TEG® enables, however, for routine monitoring of the variability in ADP receptor inhibition and of antiplatelet therapy. © 2007 Bochsen et al; licensee BioMed Central Ltd.

引用

共 20 条

[11]

Haubelt H., Anders C., Hellstern P., Can platelet function tests predict the clinical efficacy of aspirin?, Semin Thromb Hemost, 31, pp. 404-410, (2005)

[12]

Hochholzer W., Trenk D., Frundi D., Neumann F.J., Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel, Thromb Res, (2006)

[13]

Alstrom U., Tyden H., Oldgren J., Siegbahn A., Stahle E., The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment, Thromb Res, (2006)

[14]

Poulsen T.S., Mickley H., Korsholm L., Licht P.B., Haghfelt T., Jorgensen B., Using the Platelet Function Analyzer-100 for monitoring aspirin therapy, Thromb Res, (2006)

[15]

Wohltmann C.D., Franklin G.A., Boaz P.W., Luchette F.A., Kearney P.A., Richardson J.D., Spain D.A., A multicenter evaluation of whether gender dimorphism affects survival after trauma, Am J Surg, 181, pp. 297-300, (2001)

[16]

Gurbel P.A., Bliden K.P., Hiatt B.L., O'Connor C.M., Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity, Circulation, 107, pp. 2908-2913, (2003)

[17]

Jaremo P., Lindahl T.L., Fransson S.G., Richter A., Individual variations of platelet inhibition after loading doses of clopidogrel, J Intern Med, 252, pp. 233-238, (2002)

[18]

Chen L., Bracey A.W., Radovancevic R., Cooper Jr. J.R., Collard C.D., Vaughn W.K., Nussmeier N.A., Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting, J Thorac Cardiovasc Surg, 128, pp. 425-431, (2004)

[19]

Gurbel P.A., Bliden K.P., Guyer K., Cho P.W., Zaman K.A., Kreutz R.P., Bassi A.K., Tantry U.S., Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST-STENTING Study, J Am Coll Cardiol, 46, pp. 1820-1826, (2005)

[20]

McCrath D.J., Cerboni E., Frumento R.J., Hirsh A.L., Bennett-Guerrero E., Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction, Anesth Analg, 100, pp. 1576-1583, (2005)

← 1 2 →